Consensus on acromegaly complications: an update

Journal article : Review

The 16th Acromegaly Consensus Conference in September 2024 updated recommendations on diagnosis and treatment of acromegaly comorbidities. Since the 2020 acromegaly comorbidity management guideline was published, new evidence has emerged on novel and known comorbidities and new treatment approaches. Forty-three experts in the management of acromegaly reviewed the current literature and assessed changes in clinical practice standards and management. Current outcome goals were considered and updated, with a focus on the impact of current and emerging treatments of these comorbidities. Participants assessed factors that determine pharmacological choices, as well as use of specific agents in the management of the most relevant acromegaly comorbidities. We present consensus recommendations highlighting optimization of evidence-based acromegaly comorbidities management.

Authors: Giustina, A; di Filippo, L; Fleseriu, M; Pivonello, R; Petersenn, S

• Publication status: Published
• Peer review status: Peer reviewed
• Publisher: Springer
• Journal: Pituitary
• Volume: 29
• Issue: 3
• Article number: 76
• Publication date: 2026-04-29
• Acceptance date: 2026-01-12
• DOI: 10.1007/s11102-026-01639-z
• EISSN: 1573-7403
• ISSN: 1386341X, 1386-341X
• Language: English
• Keywords: Pituitary adenoma; GH receptor antagonist; Acral changes; IGF1; Growth hormone; Transpenoidal surgery; Hypertension; Arthritis; Diabetes; Somatostatin receptor ligand
• Subtype: Review